Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with chemotherapy +/- bevacizumab in EGFR-mutated NSCLC
NCT04405674Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2020
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: 1-Year Progression-Free Survival Rate. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04405674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405674.